Purpose: To evaluate the recurrence frequency and the time to recurrence of canine palpebral masses treated with debulking and cryotherapy.
Methods: Medical records of dogs that underwent debulking and cryotherapy for palpebral masses from December 2010 to November 2015 at the University of Minnesota's Veterinary Medical Center were reviewed. A telephone survey with owners was used to determine recurrence and time to recurrence.
Results: Forty-six masses (31 dogs) were included in this retrospective study. Included palpebral masses were as follows: adenomas 17/46 (37%), epitheliomas 8/46 (17.4%), papillomas 6/46 (13%), inflammatory masses 6/46 (13%), mixed adenoma-papillomas 6/46 (13%), mixed epithelioma-papillomas 2/46 (4.4%), and a melanocytoma 1/46 (2.2%). Of the seven masses that were noted to recur (7/46, 15.2%), three were mixed adenoma-papillomas (three of six adenoma-papillomas, 50%), two were epitheliomas (two of eight epitheliomas, 25%), one was a papilloma (one of six papillomas, 16.7%), and one was a melanocytoma (one of one melanocytoma, 100%). Average recurrence time was 367.9 days [range: 30-904 days]. A significant association between tumor type and tumor recurrence was found (P = .009). Adenomas were significantly less likely to recur (P = .017), and mixed adenoma-papillomas were significantly more likely to recur (P = .001).
Conclusions: Debulking and cryotherapy is an effective method of treatment for eyelid masses in dogs with a low study recurrence rate of 15.2% and average recurrence time of 367.9 days. Results also suggest that mixed adenoma-papilloma masses have a significantly higher recurrence rate than other eyelid masses, whereas adenomas had no recurrence in our study population.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/vop.12585 | DOI Listing |
BMC Ophthalmol
November 2024
Department of Oculo-Facial Plastic and Reconstructive Surgery, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Background: Pilomatrixoma is an uncommon benign skin neoplasm originating from the hair follicle. Here, we report a rare case of giant and atypical proliferating pilomatrixoma affecting the eyelid.
Case Presentation: A 47-year-old male presented with a solitary, giant mass on his left upper eyelid, which had recently shown progressive enlargement.
Zhonghua Yan Ke Za Zhi
August 2024
Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Beijing 100730, China.
A 40-year-old man presented with recurrent ocular surface masses in his left eye persisting for over a year. Despite undergoing resection of the conjunctival mass and receiving anti-inflammatory treatment at another hospital, the mass reappeared within a week post-surgery. Over the past 6 months, the mass gradually increased in size, accompanied by a decline in vision.
View Article and Find Full Text PDFTunis Med
April 2023
University of Sousse, Faculty of Medicine Ibn Jazzar Sousse, CHU Farhat Hached Sousse.
Introduction: Adult-onset asthma and periocular xanthogranuloma (AAPOX) is a rare non-Langerhans cell histiocytic disorder.
Aim: To describe the periocular clinical findings in a patient diagnosed with AAPOX, treated successfully by intralesional corticosteroids.
Case Report: A 40-year-old woman presented with bilateral eyelid swelling and adult-onset asthma.
J Fr Ophtalmol
February 2024
Service d'ophtalmologie, hôpital Principal de Dakar, avenue Nelson-Mandela, BP 3006, Dakar, Sénégal.
Introduction: Rosai-Dorfman disease (RDD) is a sinus histiocytosis with massive lymphadenopathy. This rare condition is a benign disease of unknown etiology. Bilateral orbital localization of RDD is rare.
View Article and Find Full Text PDFJ Fr Ophtalmol
February 2024
Département d'ophtalmologie, hôpital universitaire régional Jean-Minjoz, 25000 Besançon, France; Université de Franche-Comté, LNIT, 25000 Besançon, France.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!